Mizuho Reiterates $400.00 Price Target for Biogen Inc. (BIIB)

Mizuho set a $400.00 price objective on Biogen Inc. (NASDAQ:BIIB) in a research note published on Monday morning. The brokerage currently has a buy rating on the biotechnology company’s stock.

A number of other research analysts have also recently commented on the company. Vetr cut Biogen from a strong-buy rating to a buy rating and set a $319.53 price target on the stock. in a research report on Tuesday, August 29th. ValuEngine cut Biogen from a buy rating to a hold rating in a research report on Friday, September 1st. Robert W. Baird reaffirmed a hold rating and set a $290.00 price target on shares of Biogen in a research report on Friday, August 25th. SunTrust Banks, Inc. reaffirmed a buy rating and set a $354.00 price target on shares of Biogen in a research report on Tuesday, October 24th. Finally, Canaccord Genuity initiated coverage on Biogen in a research report on Friday, October 27th. They set a hold rating and a $340.00 price target on the stock. Twelve equities research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of Buy and a consensus target price of $341.89.

Biogen (BIIB) traded up $3.70 during mid-day trading on Monday, reaching $313.98. The company’s stock had a trading volume of 731,700 shares, compared to its average volume of 1,512,280. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.90 and a current ratio of 2.19. Biogen has a twelve month low of $244.28 and a twelve month high of $348.84. The stock has a market capitalization of $65,920.00, a PE ratio of 14.37, a P/E/G ratio of 1.94 and a beta of 0.72.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings results on Tuesday, October 24th. The biotechnology company reported $6.31 EPS for the quarter, beating analysts’ consensus estimates of $5.70 by $0.61. Biogen had a return on equity of 38.51% and a net margin of 29.44%. The firm had revenue of $3.08 billion for the quarter, compared to analysts’ expectations of $3.05 billion. During the same quarter in the prior year, the firm earned $5.19 EPS. The business’s revenue for the quarter was up 4.1% compared to the same quarter last year. equities research analysts forecast that Biogen will post 22.03 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This article was reported by BBNS and is owned by of BBNS. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this article can be accessed at https://baseballnewssource.com/markets/mizuho-reiterates-400-00-price-target-for-biogen-inc-biib/1781687.html.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Iguana Healthcare Management LLC lifted its holdings in Biogen by 166.7% in the 3rd quarter. Iguana Healthcare Management LLC now owns 20,000 shares of the biotechnology company’s stock worth $6,262,000 after buying an additional 12,500 shares during the period. Americafirst Capital Management LLC purchased a new stake in Biogen in the 3rd quarter worth approximately $825,000. Moors & Cabot Inc. purchased a new stake in Biogen in the 3rd quarter worth approximately $228,000. Cypress Capital Group lifted its holdings in Biogen by 83.1% in the 3rd quarter. Cypress Capital Group now owns 1,408 shares of the biotechnology company’s stock worth $441,000 after buying an additional 639 shares during the period. Finally, Belpointe Asset Management LLC purchased a new stake in Biogen in the 3rd quarter worth approximately $1,154,000. Institutional investors and hedge funds own 88.35% of the company’s stock.

Biogen Company Profile

Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).

Analyst Recommendations for Biogen (NASDAQ:BIIB)

Receive News & Ratings for Biogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Toronto Blue Jays Launch Internal Investigation on PED Use
Toronto Blue Jays Launch Internal Investigation on PED Use
Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
MLB Commissioner: New Rule for Pace-of-Play in 2018
MLB Commissioner: New Rule for Pace-of-Play in 2018
Alex Cobb Could Be Good Fit for Cubs
Alex Cobb Could Be Good Fit for Cubs
Joey Votto Is One of Baseball’s Best Hitters
Joey Votto Is One of Baseball’s Best Hitters
Hunter Pence May Become Part-Time Player
Hunter Pence May Become Part-Time Player


Leave a Reply

 
© 2006-2017 BBNS.